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interest Analyses Based on Mass 
Spectrometry imaging of Human 
Brain tumours
takuya Hiratsuka1, Yoshiki Arakawa2, Yuka Yajima3, Yu Kakimoto4, Keisuke Shima5, 
Yuzo Yamazaki5, Masahiro ikegami5, takushi Yamamoto5, Hideshi fujiwake6, 
Koichi fujimoto2, norishige Yamada7 & tatsuaki tsuruyama1,7*
imaging mass spectrometry (iMS) has been rarely used to examine specimens of human brain 
tumours. in the current study, high quality brain tumour samples were selected by tissue observation. 
further, iMS analysis was combined with a new hierarchical cluster analysis (iMS-HcA) and region of 
interest analysis (iMS-Roi). iMS-HcA was successful in creating groups consisting of similar signal 
distribution images of glial fibrillary acidic protein (GFAP) and related multiple proteins in primary brain 
tumours. This clustering data suggested the relation of GFAP and these identified proteins in the brain 
tumorigenesis. Also, high levels of histone proteins, haemoglobin subunit α, tubulins, and GFAP were 
identified in a metastatic brain tumour using IMS-ROI. Our results show that IMS-HCA and IMS-ROI are 
promising techniques for identifying biomarkers using brain tumour samples.
Recently, matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry has been 
used to identify diagnostic markers. MALDI-TOF imaging mass spectrometry (MALDI-IMS) now helps to 
identify phospholipids1,2 delivered drugs3, and peptides in various tissues4–7. Breast tumour tissue was used in 
a recently reported study of MALDI-IMS8. Reports have also been presented regarding IMS being used in the 
analysis of gastrointestinal, larynx, and ovarian tumours9,10, as well as other diseases11. In our previous study, we 
also succeeded in identifying proteins related to important myocardial functions such as ATP synthase in acute 
myocardial infarction12–14.
In the recent five years, clinical formaldehyde-fixed paraffin-embedded (FFPE) tissue has been made avail-
able for IMS studies2,12,15–17. Formaldehyde reacts with amino acid residues, such as arginine-containing amino 
groups, by methylene-bridging. The bridge makes it challenging to ionize peptides, and study is therefore difficult 
when using FFPE for IMS. For this reason, alcohol-based non-crosslinking tissue fixative could be an alternative 
fixative for multiomics tissue analysis, but its usefulness has not been fully verified18. Some studies have reported 
that the use of surfactants improved MS sensitivity using considerable limits on subjects and sample amounts for 
a stable protocol14. Angel et al. described the availability of matrix metalloproteinase enzymes to derive a better 
signal19.
In the current study, glioblastoma was selected as the disease of interest for IMS study using FFPE. 
Glioblastoma is one of the most aggressive brain tumours20. Treatment of glioblastoma includes a multidisci-
plinary approach that provides for maximal surgical resection, radiation therapy21, and chemotherapy22,23. The 
last two therapies primarily target metastatic carcinoma and malignant lymphoma24. For better treatment, it is 
crucial to differentiate glioblastoma from metastatic carcinoma and malignant lymphoma. Moreover, for earlier 
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diagnosis, proteomic approaches25 to substances in the blood of glioblastoma patients have become prevalent26. 
IMS analysis has been applied to mouse models of brain diseases27,28 as well as glioblastoma for pharmacokinetics, 
metabolomics, and lipid analysis9,29–31. However, reports of proteomic markers by IMS of glioblastoma remain 
rare. Here the analytical algorithm method has been further developed, using IMS combined with hierarchical 
cluster analysis (IMS-HCA) for recognition of the distribution pattern of ions ionized and MS combined with 
region of interest (IMS-ROI) analysis for quantification of the signals, to identify the tumour and determine the 
invasion range.
Results
Histopathology and iMS analyses. 3 glioblastoma and 1 brain metastasis of the small cell lung carcinoma 
(SCLC) samples were chosen for our study because of the high quality. The morphologic feature of SCLC (Sample 
1) was a dense sheet of small cells with ill-defined contour, finely granular nuclei, and inconspicuous nucleoli4 
(Fig. 1a). Glioblastoma is characterized by high cellularity, pleomorphism, a frequent mitotic number, the pres-
ence of vascular proliferation, and the existence of necrosis3. Three specimens of glioblastoma show some of these 
characteristics (Fig. 1b, c, d).
MALDi-iMS analyses. Samples of glioblastoma and metastatic SCLC were analysed by MALDI-IMS. 
Glioblastoma and SCLC samples were analysed separately via LC/MS or tandem MS/MS across the m/z range 
of 700–3000. We obtained MALDI-IMS signals that corresponded to a total of >500 peptides. Of these signals, 
approximately 50 spectra had sufficient intensity to obtain IMS data in each sample. MALDI-IMS and MS/MS 
data for SCLC brain tissue are shown in Figs. 2 and 3a–f, respectively. An example of the total spectrum of the 
glioblastoma (sample 2) is shown in Fig. 3g.
In Sample 1, proteins with m/z values of 944.58 (Histone H2A), 1180.80 (Histone H4), 1743.89 (Histone H2B), 
1701.83 (Tubulin α-1A), 1959.11 (Tubulin β-2A), 1208.65 (GFAP: glial fibrillary acidic protein) were identified 
via tandem MS/MS (Fig. 3a–f). As shown in the first row of Fig. 2 (SCLC), the signals of Histone H2A, Histone 
H4, and Histone H2B were found in accordance with the histopathological distribution of SCLC (Fig. 2). We 
created the MALDI-IMS in the range of a tolerance level of ±0.5 Da for each m/z gained in sample 1.
The signal of the glial fibrillary acidic protein (GFAP) was identified in samples 2–4 from the total spectrum 
by inputting the above m/z values. The IMS of haemoglobin subunit α(HBA) was obtained in the haemorrhagic 
region of sample 4 shown in Fig. 2 (indicated by arrows). Furthermore, IMS of Histone H2A, Histone H4, Histone 
H2B, Tubulin α-1A, and GFAP were obtained in the glioblastoma tissues (sample 2–4) (Fig. 2).
Figure 1. Histological images of metastatic lung small cell carcinoma (a) and glioblastoma (b–d) in 
haematoxylin and eosin staining. (a) (sample 1) Metastatic small cell lung carcinoma has a dense sheet of small 
cells with scanty cytoplasm, and finely granular nuclei. (Original magnification: X200). Scale bars, 100 µm in 
(a–d). (b) (sample 4) Cellular lesion of glioblastoma shows high cellularity, prominent cytologic atypia and 
pleomorphism. (Original magnification: X200) (c) (sample 4) Haemorrhage among tumour cells. (Original 
magnification: X200) (d) (sample 4) Necrosis is surrounded by the pseudo-palisading arrangement of nuclei of 
tumour cells. (Original magnification: X100).
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iMS combined with HcA for the selected proteins. First, MALDI-IMS combined with HCA 
(IMS-HCA) with Ward method was performed using metastatic tumour sample 1. IMS-HCA showed a cluster 
including Histone H2A, H4, and Histone H2B (Tumour, Fig. 4a). In contrast, other proteins from normal region 
belonged to different clusters (Normal, Fig. 4a), indicating that IMS-HCA method was available for distinction 
of the tumour region from the normal region. In sample 2, IMS-HCA with Ward method showed corresponding 
clusters of GFAP, Histone H4, and Tubulin α-1A (Fig. 4b). In sample 3, consistent with the IMS data in Fig. 2, 
the signals of GFAP, Tubulin α-1A, Histone H2B and Tubulin β-2A formed a close cluster in IMS-HCA with 
Ward method (Fig. 4c). Also, the HBA signal in the cerebral blood vessels away from the glioblastoma region 
formed a cluster separate from the cluster of GFAP signals. The HBA clustering result revealed that glioblas-
toma and blood vessel placement are irrelevant in this specimen (Fig. 4d). As described above, the correlation 
between two-dimensional distribution of signal intensity in IMS data and histopathology could be well verified 
by IMS-HCA. The HCA of samples 1, 2, 3, and 4 with group average method showed the same clustering results 
regarding the relationship among the clusters to which the proteins belonged, except the dissimilarity (distance) 
as demonstrated in Supplementary Fig. 1a–d.
iMS-HcA for the total proteins. First, IMS-HCA was performed using metastatic SCLC tumour sample 1 
with Ward method (Fig. 5a). IMS-HCA showed a corresponding cluster of Histone H2A, Histone H4, and H2B, 
whereas GFAP and Tubulin β-2A belonged to different clusters. This result is compatible with that of IMS-HCA 
for the selected proteins in Fig. 4a. Next, in sample 2, IMS-HCA with Ward method showed that the GFAP and 
Tubulin α-1A belonged to clusters, which was compatible with the above IMS-HCA for the selected proteins in 
Fig. 4b (Fig. 5b). In sample 3, IMS-HCA with Ward and other methods could not obtain clustering because of 
the lower intensity of the signal. In sample 4, IMS-HCA formed a close cluster of Histone H2A and GFAP, and 
distant cluster of HBA and GFAP (Fig. 5c). The HCA of samples 1, 2, and 4, with group average method, showed 
the same clustering results, regarding the relationship between the proteins except the dissimilarity (distance) as 
shown in Supplementary Fig. 2a–c.
IMS-ROI quantification of peptides in tumour region. For MALDI-IMS-ROI (IMS-ROI) analysis, the 
tumour region was independently margined by three pathologists, and the ROI was nearly shared. We measured 
the intensity of the signals of Histone H2A, Histone H4, Histone H2B, Tubulin β-2A, Tubulin α-1A, GFAP, and 
HBA using Imaging MS Solution (sample 1: N = 369, sample 2: N = 514, sample 3: N = 532, sample 4: N = 925). 
These statistics are shown in Table 2. The average intensities of Histone H2A and Histone H4 were significantly 
Figure 2. MALDI-IMS analyses of samples. Each identified protein is shown at the top. Each m/z value is noted 
above the images of samples 1–4. Scale bars: 600 μm (sample 1), 900 μm (samples 2 and 3), or 400 μm (sample 4). 
Each identified protein is shown at the top. The small white arrow indicates the haemorrhagic region in sample 3 
and sample 4. SCLC, small cell lung cancer.
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higher than other peptides in the metastatic tumour region in sample 1. Specifically, the average intensity of GFAP 
was lowest in all peptides except Nestin (Fig. 6a, Supplementary Table 1).We found the average intensity of GFAP 
was significantly higher than those of Histone H2 and Histone H4 (Fig. 6b, Supplementary Table 1) in sample 2. 
The average intensity of Histone H2A, Histone H4, Histone H2B, Tubulin β-2A, Tubulin α-1A, and GFAP in 
sample 3 was high in the ROI (Fig. 6c, Supplementary Table 1). In sample 4, we found that the average intensities 
of Histone H2A and GFAP (m/z = 1208) were significantly higher. Additionally, the average intensity of HBA 
was high in the tumour region, indicating that the aforementioned haemorrhage in the tumour region (Fig. 6d, 
Supplementary Table 1). GFAP was high in the tumour regions of all glioblastoma samples.
comparison of peptides in tumour and normal region by iMS-Roi analysis. We calculated the 
average intensity of peptides by IMS-ROI analysis using Imaging MS Solution. In samples 1 and 3, each sample 
contained both tumour and normal tissue. The tumour and normal regions were selected as the ROI. We meas-
ured the intensity of the signals of Histone H2A, Histone H4, Histone H2B, Tubulin β-2A, Tubulin α-1A and 
GFAP (m/z 1208) in each ROI (sample 1 tumour: N = 369, normal: N = 730; sample 3 tumour: N = 532, normal: 
N = 231).
Figure 3. MS profiling of SCLC and glioblastoma. (a) Tandem mass spectrum of the precursor ion in SCLC 
(sample 1) at m/z 944.55. A database search identified the ion at m/z 944.55 as a fragment of Histone H2A type 
1-A, P = 0.024, (b) Tubulin α1-A, m/z 1701.92, P = 0.0094, (c) Tubulin β2-A, m/z 1620.94, P = 1.4 × 10−5, (d) 
Histone H2B type 1-B, m/z 1743.75, P = 0.051, (e) Histone H4, m/z 1180.66, P = 5.1 × 10−5, (f) Glial Fibrillary 
Acidic Protein (GFAP), m/z 1208.6, P = 0.029. (g) MS profiling of glioblastoma (sample 2).
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According to Cohen’s d-value-based IMS-ROI analysis, in sample 1, we observed that the average intensities 
of Histone H2A, Histone H4, Histone H2B, and were higher in the tumour region than those in the normal 
region (P- and d-values; significant and medium, respectively, in Table 2). The average intensities of Tubulin 
β-2A, Tubulin α-1A and GFAP (m/z 1208) were lower in the metastatic tumour region than in the normal region 
(small) (Fig. 7a and Table 1).
Similarly, in sample 3, we found the average intensities of not only Histone H2A, Histone H4, Histone H2B, 
Tubulin β-2A, and Tubulin α-1A, but also GFAP (m/z 1208) were higher in the glioblatoma region than the 
normal region (all proteins for P-values, Histone H4 for d-value) (Fig. 7b and Table 1). The standard deviation of 
intensity data in Fig. 7 was significantly variable than that of the normal region as shown in the boxplot, suggest-
ing the pleomorphism of glioblastoma region.
Discussion
IMS research has recently made significant progress in determining the distribution of small, specific molecules 
in tissues, namely in the fields of lipid identification and brain tumor cell clusters in brain tissue. On the same 
token, it has now found use in peptide identification. Our studies show that the IMS method has been extended 
to increase the usability of FFPE tissue significantly.
Our application of imaging MS Solution has facilitated the evaluation of the signal intensity distribution 
patterns. The similarity between clusters was assessed via the geometric distance between the pixels. There are 
several methods for clustering. Herein, we consider that the Ward methods, and the group average method are 
reasonable because these methods analyze all pixels’ intensity. In contrast, only a part of the pixels was subjected 
to the analysis in other clustering methods. The group average method is a method in which the average of the 
inter-sample distances of all combinations between clusters is set as the inter-cluster distance. The Ward method 
is as follows. First, assume a new cluster that combines two clusters. Next, let L be the sum of squares of the 
distance between the centre of gravity of the new coupled-cluster and each sample. Next, let L (P) and L (Q) be 
the sum of the squares of the distance between the centre of gravity of the two original clusters and the sample 
inside. Finally, clusters that minimize Δ = L − L (P) − L (Q) are combined to obtain a new cluster. Forming a 
new connected cluster repeats minimizing errors because the information is reduced compared to the original 
cluster distribution. The Ward method reflects the actual state of the cluster more quickly than the group aver-
age method and it is often used as a default. The Ward method is employed because a more general result can 
be obtained compared to the group average method. However, in the current study, the Group average method 
and Ward methods showed similar clustering (Figs. 4, 5, Supplementary Figs. 1, 2). We identified that 50 of the 
500 peptides’ spectra in the HCA show high signal intensity. However, many did not meet our pre-set statistical 
accuracy requirements in the current study. Therefore, only the proteins shown in the cluster tree now satisfy the 
Figure 4. Cluster analysis of the two-dimensional distribution of the selected peptides. The data from two-
dimensional distributions were used to calculate a cluster dendrogram. The vertical axis represents dissimilarity, 
while the m/z values are represented on the horizontal axis. HCA analysis, with Ward method (a) sample 1, (b) 
sample 2, (c) sample 3, and (d) sample 4.
6Scientific RepoRtS |         (2020) 10:5757  | https://doi.org/10.1038/s41598-020-62176-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
statistical accuracy. The reason for the lack of statistical accurtuacy was that the short peptide sequence could not 
completely rule out the possibility of other proteins according to Mascot search engine (see Methods).
Furthermore, we adopted IMS-HCA to evaluate the two-dimensional distribution information more accu-
rately. Each pixel m/z data set provides similarities between peptide distribution patterns. Of particular note 
Figure 5. Cluster analysis of the two-dimensional distribution of the whole spectrum. The data from two-
dimensional distributions were used to calculate a cluster dendrogram. The vertical axis represents dissimilarity, 
while the m/z values are represented on the horizontal axis. HCA analysis with Ward method: (a) sample 1, 
(b) sample 2, (c) sample 4. HB, HBA; TB, Tubulin β-2A; G, GAFP; TA, Tubulin α-1A; H2A, Histone H2A; H4, 
Histone H4.
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is that Histone H2A belongs to the tumour cluster in both metastatic SCLC. Previous studies have shown that 
Histone H2A is highly detectable by mass spectrometry of colorectal cancer tissue2. In both IMS-HCA for the 
selected protein (peptide) in Fig. 4 and IMS-HCA for whole peptides in Fig. 5, cluster classification that closely 
matched the two-dimensional distribution pattern of IMS was confirmed. The ability for pattern similarity to be 
expressed quantitatively by the distance between clusters indicates a correlation between peptides that belong 
to closer clusters. GFAP is one of the well-known diagnostic markers for glioblastoma, but the proteins forming 
clusters close to those of GFAP may relate to the pathogenesis of glioblastoma. Here, Tubulin α-1A and Histone 
H2A belonged to a relatively close cluster of GFAP (Fig. 5b, Tubulin α-1A; Fig. 5c, Histone H2A; Supplementary 
Fig. 1b, Tubulin α-1A; Supplementary Fig. 1c, Histone H2A). In this way, based on this IMS-HCA data, the distri-
bution similarity of Histone H2A, Tubulin α-1A, and GFAP may suggest the correlation of the first two proteins 
in glioblastoma development or progression.
Sample 1 m/z Mean (T) SD (T) Mean (N) SD (N) p value d value Effect
Histone H2A(m/z 944.542) 3015.8 1777.8 794 512.4 5.20E-93 2 significant
Histone H4 (m/z 1180.705) 917.3 500 408.8 174.8 4.95E-73 1.6 significant
Histone H2B (m/z1743.885) 589.9 287.1 414.5 176.3 3.12E-25 0.8 significant
Tubulin β-2A (m/z 1620.955) 693.4 355.5 922.7 538.4 1.87E-11 0.5 significant
Tubulin α-1A (m/z 1701.890) 452.6 188.1 659.6 310.6 1.24E-32 0.8 medium
GFAP (m/z 1208.708) 402.1 150.5 503.7 234.3 1.09E-15 0.5 medium
Sample 3 m/z Mean (T) SD (T) Mean (N) SD (N) p value d value Effect
Histone H2A (m/z 945.728) 125.9 40.8 96.3 36.6 2.64E-39 0.26 small
Histone H4 (m/z 1181.735) 164.9 59.9 123.4 48.4 1.44E-58 0.5 medium
Tubulin β-2A (m/z 1621.380) 162.9 65.2 110.6 48.8 2.87E-95 0.31 small
Tubulin α-1A (m/z 1703.420) 157 60 111.3 47.2 6.14E-92 0.3 small
GFAP (m/z 1208.732) 169.4 54.1 128.2 50.5 3.38E-65 0.24 small
Table 2. Statistical analysis using IMS-ROI. Tumour (T) and Normal (N) represent intensity.
Figure 6. Quantification of peptides in the tumour region. On the vertical axis, the average intensity in tumour 
region of (a) sample 1, (b) sample 2, (c) sample 3, and (d) sample 4 is shown, and on the horizontal axis, the m/z 
values of individual protein-derived peptides are shown. (a) IMS of Histone H2A and (b–d) IMS of GFAP are 
shown.
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IMS-ROI analysis was performed to test the difference between tumour and normal ROI intensity for each 
batch of imaging data12. When analysis was performed with separate ROIs assigned to the tumour region and the 
normal region of the brain tissue, molecules specific to the tumour region were detected. The parametric Student’s 
t-test achieved a match with a significance threshold of P < 0.01, and the d-value was adopted as before. IMS-ROI 
analysis was also used to compare disease and normal region protein intensities to determine potential biomark-
ers in tumour tissue. As shown in Tables 2 and S1, and Fig. 7 (sample 1), the intensities of histones H2A, H4, and 
H2B identified by ROI analysis have a higher average value, and a higher standard deviation of the signal intensity 
in the tumour region than in the normal region. The intensities of Tubilin α1-A and GFAP have the same stand-
ard deviation in the normal region as in the tumour region, and the mean value is higher in the normal region. 
In contrast, the three histones, H2A, H4, and H2B, having large standard deviations in the tumor region may 
represent heterogeneity of the metastatic tumour. This is probably a characteristic of small cell carcinoma tumour 
tissue. It is highly likely that other proteins show the same level of strength because they are uniformly expressed 
in the normal tissue, and they are not related to tumours. However, in glioblastoma in sample 3, H2A, H4, 
Tubulin β-2A, Tubulin α-1A, and GFAP show more stable higher intensities than in the normal region, suggest-
ing a difference between metastatic lung tumors and glioblastoma.
Our study is limited to the small number of patients, and the data do not strongly determine the extent of 
brain tumour. Nevertheless, IMS shows a correlation between GFAP and the brain tumour markers H2A and 
Tubulin α-1A, suggesting tumour development. In the future, more brain tumour markers will be identified 
by IMS combined with IMS-HCA and IMS-ROI. In fact, reducing image margins is important for minimizing 
mismatches in the amount of peptide in the sample. This is worth considering in future researches. As the devel-
opment of this platform progresses, we will report on this elsewhere.
Figure 7. Quantification of peptides in tumour and normal regions by IMS-ROI analysis. (a) sample 1, (b) 
sample 3. The box plot shows the distribution of intensity of all pixels in a m/z image in each tumour and 
normal region. Box plot explanation: upper horizontal line of box, 75th percentile; lower horizontal line of box, 
25th percentile; horizontal bar within box, median; upper horizontal bar outside box, 90th percentile; lower 
horizontal bar outside box, 10th percentile. The histogram shows the frequency of intensity of all pixels of the 
m/z image each tumour and normal region. The histogram vertical axes represent the frequency of pixels. The 
horizontal axes represent intensity. The two images on the left side show each ROIs. The red lines express the 
border of the ROI for tumour region. The blue lines express the ROI of the normal region. The image at the left 
coloum represents IMS of Histone H2A.
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Methods
patients. This study and all its protocols were approved by the Medical Ethics Committee of the Graduate 
School and Faculty of Medicine, Kyoto University, Japan. We obtained informed consent from all study partic-
ipants, who donated their tumours in return for receiving its surgical excision. All experiments and image data 
analyses were carried out according to the relevant guidelines and regulations, including Ethical Guidelines for 
clinical studies by the Ministry of Health, Labour, and Welfare, as well as the Ministry of Education, Culture, 
Sports, Science, and Technology. The pathological diagnosis of all excised tumours was either glioblastoma or 
SCLC.
tissue preparation. Brain tissue was prepared with 10% (v/v) formaldehyde in phosphate buffer (pH 7.2) 
immediately after excision. After fixation, tissues were embedded in paraffin. These paraffin-embedded blocks 
were sliced into 4 μm sections for microscopic observation with haematoxylin and eosin.
FFPE tissues were deposited on indium tin oxide-coated (ITO) glass slides (Sigma–Aldrich, St. Louis, MO) 
and were treated in 800 μL of the pre-treatment buffer (0.1 M NH4HCO3 and 30% (v/v) CH3CN) in an incubation 
chamber for the brain tissues2. Incubation in pre-treatment buffer, heating, and digestion with trypsin solution 
including 2.5 mM NH4HCO3 and 10% (v/v) CH3CN were added to the chambers as described previously in 
detail2,12–14. By these incubation and steaming procedures (SSP), we succeeded in increasing the ionization effi-
ciency of the protein on the FFPE specimen to approximately 4–5 times of the conventional method, and reduc-
ing a nonspecific signal noise2. Without the SSP method, we could not have gained the sufficient intensity form of 
the ionized peptides in the current study.
Matrix deposition. Four sample slides were placed in a slot on a MALDI target plate and attached with 
conductive tape. The prepared matrix solution was 2,5-dihydroxybenzoic acid (50 mg/mL) in 50% methanol 
and 0.05% trifluoroacetic acid. The matrix solution was added to the sections using a CHIP-1000 chemical inkjet 
printer (Shimadzu, Kyoto, Japan) with a droplet size of 5-nL by micro-spotting in 25 cycles of 200 pL per spot at a 
spatial distance of 250 μm. After spotting, the target plate was dried in a desiccator at 20 °C.
tandem MS, statistical analysis and MS imaging (iMS). We collected MS/MS data, using a 
MALDI-QIT-TOF MS (AXIMA Resonance and MALDI-7090; Shimadzu) equipped with a 337 nm pulsed nitro-
gen laser run at a frequency of 10 Hz for gaining data of sample 1 for the identification of the protein in IMS. 
Thereafter, we exported the spectra to the Mascot search engine (Matrix Science, Boston, MA), using the follow-
ing parameters: taxonomy = Homo sapiens; MS/MS tolerance = 0.3 Da; enzyme = trypsin; missed cleavage = 
1: database = SwissProt; and MS tolerance = 0.2 Da. We identified peptides and proteins, using the Paragon 
algorithm provided with ProteinPilot 4.5 Beta (AB SCIEX, Danaher, Washington, D.C.) combined with the 
UniProt-Swiss-Prot database (version 2010–6, Homo sapiens). We assigned matches to a significance threshold 
of P < 0.0513. False discovery rate (FDR) analysis was performed after using the Proteomic System Performance 
Evaluation Pipeline (PSPEP) software (Danaher). We quantified peptides, using Protein Quantitation 1.0 
MicroApp (PQMA). Moreover, we analyzed liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
datasets for all samples, using ProteinPilot 4.5 beta. The data file was imported to the Peak View 1.1.1 platform, 
using PQMA. Protein abundance was obtained, using Marker View 1.2.1. We selected peptides with a confi-
dence > 0.95 for export. The m/z values corresponding to the proteins identified in tandem MS of sample 1 were 
assigned with two decimal places equal to the spectra of samples 2–4. The spectra were recorded in positive ion 
mode in a m/z range of 700–3000. Calibration was performed with a mixed solution of angiotensin II, and adren-
ocorticotropic hormone fragment. The pixel sizes are: Sample 1: 1180 pixels, Sample 2: 861 pixels, Sample 3: 1125 
pixels, and Sample 4: 1116 pixels.
protein extraction and Lc/MS. The proteins identified in IMS were actually detected in the data of three 
brain tumor samples by LC/MS, and included in the higher coverage (%) (>5.0) group (Supplementary Table S2–4. 
The LC/MS measurement method at that time is shown below this section32. Samples were homogenized and 
Observed m/z Sequence Protein name Expect (P < 0.05)
944.55 R.AGLQFPVGR.I Histone H2A type 1-A (H2A1A_HUMAN) 0.024
1180.66 R.ISGLIYEETR.G Histone H4 (H4_HUMAN) 5.10E-05
1743.75 K.AMGIMNSFVNDIFER.I Histone H2B type 1-B (H2B1B_HUMAN) 0.051
1620.94 R.LHFFMPGFAPLTSR.G Tubulin beta-2A chain (TBB2A_HUMAN) 1.40E-05
1620.78 R.LHFFMPGFAPLTSR.G Tubulin beta-2A chain (TBB2A_HUMAN) 1.10E-05
1701.92 R.AVFVDLEPTVIDEVR.T Tubulin alpha-1A chain (TBA1A_HUMAN) 0.00059
1959.22 K.GHYTEGAELVDSVLDVVR.K Tubulin beta-2A chain (TBB2A_HUMAN) 0.0094
1208.60 R.EAASYQEALAR.L Glial fibrillary acidic protein (GFAP_HUMAN) 0.029
1208.64 R.EAASYQEALAR.L Glial fibrillary acidic protein (GFAP_HUMAN) 0.036
1215.68 R.DNLAQDLATVR.Q Glial fibrillary acidic protein (GFAP_HUMAN) 0.025
1263.73 R.LEAENNLAAYR.Q Glial fibrillary acidic protein (GFAP_HUMAN) 0.00037
1529.74 K.VGAHAGEYGAEALER.M Hemoglobin subunit alpha (HBA_HUMAN) 7.10E-05
Table 1. List of peptide peaks identified by MS/MS analysis in the FFPE human brain tissue.
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suspended in 20 μL of 0.1 M NH4HCO3, containing 30% (v/v) CH3CN. After centrifuge, incubation, and cooling, 
samples were incubated in trypsin solution at 37 °C overnight. We added 10 mM DTT, and heated the digests at 
95 °C for 5 min. After drying, we re-suspended them in 0.1% TFA containing 2% CH3CN. The samples were sepa-
rated, using a nano-flow reverse-phase LC (NanoLC-Ultra System; Eksigent, Dublin, CA). We injected an aliquot 
of 5 μL of each sample into a trap column, and washed it for 10 min, using 0.1% formic acid. Peptides were eluted 
for further analyses, using Triple TOF 5600 system (AB SCIEX, Framingham, MA) with a nano-electrospray ion-
ization source (NanoSpray; AB SCIEX, Framingham, MA). We performed MS/MS scans, using a collision energy 
of 35 kV with unit-resolution.
iMS-Roi analysis. Tumour ROI on the pathological image was diagnosed by two pathologists and manually 
mapped on the m/z image. Intensity values for all pixels in the ROI (tumour or metastatic tumour focus region) 
were represented by m/z images of each peptide. In IMS-ROI analysis, P value was evaluated by Student t-test and 
Cohen’s d value by d s s n nh n n( )((( 1) ( 1) )/( 2))i h i i h i h
2 2 1/2σ σ= − − + − + − −  where si and sh represent the 
average signal strength of the ROI and normal region pixels, respectively. ni and nh are the ROI and normal pixel 
numbers, respectively. σi and σh represent the standard deviation of pixel ROI and normal region intensity, 
respectively33,34. Cohen’s criteria are as follows: d < 0.2, not important. 0.2 < d < 0.5, small; 0.5 < d < 0.8, medium; 
d > 0.8, significant. We determined that there was an appreciable difference between the normal region and the 
tumour region when 0.5 < d.
Hierarchical cluster analysis (HcA). MS Solution v1.20 (Shimadzu) was used for both IMS-HCA with 
the Ward method and the group average method. When HCA was performed, the Euclidean distance between 
the data matrix of each image was measured. The images that were close together were combined into one large 
cluster, and then the distance between each newly grouped individual cluster was calculated. By repeating this 
process, clustering was performed hierarchically on the dendrogram. The vertical axis represents distance, and 
the m/z value was represented on the horizontal axis.
Data availability
The datasets generated and/or analysed during the current study are available from the corresponding author 
upon reasonable request.
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